LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

Days after the pharmaceutical company Amgen agreed to pay $71 million to 48 states to resolve allegations that it illegally marketed the anemia drug Aranesp, PharMerica Corp. has agreed to a ...

Aranesp once looked like Amgen Inc.’s supernova, predicted to turn into another blockbuster product for the Thousand Oaks biotech giant, much like its predecessor anti-anemia drug Epogen. These days, ...

Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. The Thousand Oaks, Calif., company pleaded ...

The Food and Drug Administration called on physicians yesterday to warn cancer patients undergoing chemotherapy that certain anti-anemia drugs led to tumor growth and decreased survival in some ...